Screener
BioMarin Pharmaceuticals BMRN Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
FAQ
- What is BioMarin Pharmaceuticals's cumulative cost basis?
- BioMarin Pharmaceuticals (BMRN) reported cumulative cost basis of $874.01M in Q2 2026.
- How has BioMarin Pharmaceuticals's cumulative cost basis changed year-over-year?
- BioMarin Pharmaceuticals's cumulative cost basis decreased by 54.9% year-over-year, from $1.94B to $874.01M.
- What is the long-term trend for BioMarin Pharmaceuticals's cumulative cost basis?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's cumulative cost basis has grown at a 8.8% compound annual growth rate (CAGR), from $1.35B to $2.05B.
- What does cumulative cost basis mean?
- The aggregate historical cost basis of assets or liabilities before adjustments for fair value, impairment, or amortization.
Ask your AI about BioMarin Pharmaceuticals's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude